Fever reports 7% revenue and 9% adjusted EBITDA growth
Fever said revenue rose 7% year-over-year, with strong US and UK performance and portfolio diversification. Adjusted EBITDA increased 9%, and a £60m share buyback is underway. FY26 guidance is unchanged.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.